PetVivo Holdings (PetVivo Holdings) DeferredTaxAndRevenue : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is PetVivo Holdings DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

PetVivo Holdings's current deferred tax and revenue for the quarter that ended in Dec. 2023 was $0.00 Mil.

PetVivo Holdings DeferredTaxAndRevenue Historical Data

The historical data trend for PetVivo Holdings's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PetVivo Holdings DeferredTaxAndRevenue Chart

PetVivo Holdings Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

DeferredTaxAndRevenue

Get a 7-Day Free Trial

PetVivo Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
DeferredTaxAndRevenue	Get a 7-Day Free Trial															-	-	-	-	-

PetVivo Holdings DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of PetVivo Holdings's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

PetVivo Holdings (PetVivo Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » PetVivo Holdings Inc (OTCPK:PETVW) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

PETV:USA

Address

5251 Edina Industrial Boulevard, Edina, MN, USA, 55439

Website

https://www.petvivo.com

PetVivo Holdings Inc is an emerging biomedical device company. The group is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. A key strategy of the company is to leverage human therapies for the treatment of companion animals cost-effectively and in a timely manner. The accelerated timeline to revenues for veterinary medical devices is a key component of this strategy, which enter the market much earlier than pharmaceuticals and biologics. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of nineteen patents.